Skip to main content

[18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab Cover

.blurhash-client-img { display: none !important; }

[18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab

Radiology and Oncology

Volume 54 (2020): Issue 3 (September 2020)

By: Damijan Valentinuzzi, Martina Vrankar, Nina Boc, Valentina Ahac, Ziga Zupancic, Mojca Unk, Katja Skalic, Ivana Zagar, Andrej Studen, Urban Simoncic, Jens Eickhoff and Robert Jeraj

Open Access

|Jul 2020

Figures & tables

Additional files

Articles in this issue

DOI: https://doi.org/10.2478/raon-2020-0042 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099

Journal RSS Feed

Language: English

Page range: 285 - 294

Submitted on: Apr 30, 2020

|

Accepted on: Jun 5, 2020

|

Published on: Jul 29, 2020

Published by: Association of Radiology and Oncology

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

[¹⁸F]FDG PET/CT,

non-small-cell lung cancer,

radiomics analysis,

Related subjects:

Clinical medicine,

Internal medicine,

Haematology, oncology,

© 2020 Damijan Valentinuzzi, Martina Vrankar, Nina Boc, Valentina Ahac, Ziga Zupancic, Mojca Unk, Katja Skalic, Ivana Zagar, Andrej Studen, Urban Simoncic, Jens Eickhoff, Robert Jeraj, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 54 (2020): Issue 3 (September 2020)

Previous article